Goals and challenges of developing a patient focused myeloma center of excellence - Curetalks

Goals and challenges of developing a patient focused myeloma center of excellence

The multiple myeloma treatment field has undergone several changes over the past 10-20 years. The average overall survival has changed from 1-3 years to 10-20 years. Yet, there is no established curative therapy for multiple myeloma. However, advanced monitoring with minimal residual disease (MRD) testing, targeted imaging, and cutting-edge molecular profiling of residual disease post-therapy will drive the field forward in the coming few years. With better identification of residual disease as well as detection of early recurrences, patients can look forward to  improved remission-free follow-ups.

Multiple myeloma survivor and advocate, Gary Petersen talks to world renowned multiple myeloma specialist Dr. Carl Ola Landgren as part of the CureTalks with Gary series. Gary discusses the goals and challenges of developing a best of class patient-focused myeloma center of excellence with Dr. Landgren. 

Hematologic oncologist Ola Landgren, MD, PhD, was recently appointed the inaugural leader of a new research program, Experimental Therapeutics, at Sylvester Comprehensive Cancer Center at the University of Miami Health System and the Miller School of Medicine. Dr. Landgren, who was Chief of Myeloma Service for the past 6 years at Memorial Sloan Kettering Cancer Center, will also serve as Chief of the Myeloma Program at Sylvester. 

Panelists

Talk Recorded on Sep 08, 2021, 03:15 pm EST </> Embed
<iframe src="https://www.curetalks.com/event-embed/4150" id="frame" frameborder="0" scrolling="no" style="width: 100%; overflow: hidden; min-height: 500px;" ></iframe>

Submit a question for the panelists or leave a comment below.

Your email address will not be published. Required fields are marked *

Comments/Questions

  1. B

    Dr. Landgren – In establishing a world class cancer myeloma center at Sylvester, what new technologies will you be bringing to patient care – e.g. imaging, mass spec etc?
    Also as you implement clinical trials will you focus on certain cohorts e.g. SMM and NDMM or will you also have offerings for RRMM?
    Bonnie Falbo